Oryzon to Attend the 34th Annual J.P. Morgan Healthcare Conference in San Francisco
BARCELONA, SPAIN and CAMBRIDGE MA.
• The company will also present the latest advances in its LSD1 programs at the 8th Annual Biotech Showcase
Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced today that Dr. Carlos Buesa, Oryzon’s Chief Executive Officer, will attend the 34th Annual J.P. Morgan Healthcare Conference on January 11–15, 2016 at the Westin St. Francis in San Francisco to discuss with industry leaders the potential of epigenetics in devastating diseases.